Basic information Safety Supplier Related

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)

Basic information Safety Supplier Related

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE) Basic information

Product Name:
DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)
Synonyms:
  • (17α)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one OxiMe
  • (17α)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one-d6 OxiMe
  • (-)-NorelgestroMin-d6
  • (17alpha)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one oxime
  • (E)- and (Z)-17-Deacetylnorgestimate mixture
  • Norgestimate metabolite Norelgestromin
  • 17-Desacetyl Norgestimate ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)
  • Deacetylnorgestimate (Mixture of (E)- And (Z)-17-Deacetyl Norgestimate)
CAS:
53016-31-2
MF:
C21H29NO2
MW:
327.46
Product Categories:
  • Various Metabolites and Impurities
  • Intermediates & Fine Chemicals
  • Metabolites & Impurities
  • Pharmaceuticals
  • Steroids
Mol File:
53016-31-2.mol
More
Less

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE) Chemical Properties

Melting point:
107-109°C
Boiling point:
491.9±45.0 °C(Predicted)
Density 
1.23±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,2-8°C
solubility 
DMF: 11 mg/ml; DMSO: 10 mg/ml; Ethanol: 12 mg/ml; PBS (pH 7.2): 0.25 mg/ml
form 
A solid
pka
12.22±0.60(Predicted)
color 
White to off-white
CAS DataBase Reference
53016-31-2
More
Less

Safety Information

HS Code 
2937230000
More
Less

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE) Usage And Synthesis

Description

Ortho Evra@ is the first birth control transdermal patch and contains a combination of norelgestromin and ethinylestradiol. The patch can be applied to the buttocks, lower abdomen, upper torso or arms; changed weekly for 3 weeks, followed by a patch-free week. Norelgestromin is the active metabolite produced following oral administration of norgestimate, the progestin component of the contraceptive, Ortho-Cyclen?. The half-life value of norelgestromin was approximately 28 h. Following application, norelgestromin rapidly appeared in the serum, reached a plateau by approximately 48h and was maintained at an approximate steady state throughout the wear period. Hepatic metabolites of norelgestromin included norgestrel and various hydroxylated and conjugated metabolites that were eliminated by renal and fecal pathways. Ortho Evra produced ovarian suppression and cycle control. It was significantly more effective in suppressing follicular development than the leading oral contraceptive Triphasil? (ethinyl estradiol/levomorgestrel); was as effective in preventing pregnancies and had similar tolerability profile. The patch offers 99% efficacy when used appropriately, as shown by three clinical trials. However, a statistically significantly greater proportion of pregnancies occurred among women weighing 90 kg or more. Ortho Evra? was well tolerated, with 2.6% of women discontinuing treatment due to mild to moderate reactions at the site of application. Thus, the patch combined the efficacy of oral contraceptives with the convenience of just once-weekly dosing.

Chemical Properties

White Solid

Originator

Johnson & Johnson (USA)

Uses

E/Z-17-Deacetylnorgestimate is a metabolite of Norgestimate. A contraceptive for birth control used by women.

Definition

ChEBI: Norelgestromin is a steroid. It derives from a hydride of an estrane.

brand name

ORTHOEVRA (R. W. Johnson); EVRA (R. W. Johnson) Note— Norelgestromin has appeared in the literature as 17- deacylnorgestimate.

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)Supplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Email
sj_scrc@sinopharm.com
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com